blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2208073

EP2208073 - BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.11.2020
Database last updated on 29.07.2024
FormerThe patent has been granted
Status updated on  13.12.2019
FormerGrant of patent is intended
Status updated on  06.11.2019
FormerExamination is in progress
Status updated on  19.12.2016
Most recent event   Tooltip24.06.2022Lapse of the patent in a contracting state
New state(s): CY, HU, MT		published on 27.07.2022  [2022/30]
Applicant(s)For all designated states
Nordic Bioscience A/S
Herlev Hovedgade 207
2730 Herlev / DK
[2010/29]
Inventor(s)01 / KARSDAL, Morten
Holsteinsgade 21
3. th
2100 København Ø / DK
02 / QVIST, Per
Taarbæk Strandvej 103 G
2930 Klampenborg / DK
03 / BARASCUK, Natasha
Herninggade 21
3.tv
2100 København Ø / DK
 [2020/03]
Former [2010/29]01 / KARSDAL, Morten
Holsteinsgade 21 3. th
DK-2100 København Ø / DK
02 / QVIST, Per
Taarbæk Strandvej 103 G
DK-2930 Klampenborg / DK
03 / BARASCUK, Natasha
Herninggade 21 3.tv
DK-2100 København Ø / DK
Representative(s)Beck Greener LLP
Fulwood House
12 Fulwood Place
London WC1V 6HR / GB
[2020/03]
Former [2014/16]Beck Greener
Fulwood House
12 Fulwood Place
London WC1V 6HR / GB
Former [2010/29]Smart, Peter John
Beck Greener Fulwood House 12 Fulwood Place London
WC1V 6HR / GB
Application number, filing date08847014.104.11.2008
[2010/29]
WO2008EP64946
Priority number, dateGB2007002171305.11.2007         Original published format: GB 0721713
GB2007002274820.11.2007         Original published format: GB 0722748
GB2008000281415.02.2008         Original published format: GB 0802814
[2010/29]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009059972
Date:14.05.2009
Language:EN
[2009/20]
Type: A2 Application without search report 
No.:EP2208073
Date:21.07.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 14.05.2009 takes the place of the publication of the European patent application.
[2010/29]
Type: B1 Patent specification 
No.:EP2208073
Date:15.01.2020
Language:EN
[2020/03]
Search report(s)International search report - published on:EP17.09.2009
ClassificationIPC:G01N33/68
[2010/29]
CPC:
C07K14/775 (EP,US); G01N33/68 (CN); G01N33/6878 (US);
C07K14/77 (US); C07K14/78 (US); C12Q1/37 (EP,US);
G01N33/542 (EP,US); G01N33/577 (US); G01N33/6893 (US);
G01N2800/32 (EP,US); G01N2800/50 (US); G01N2800/52 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2020/03]
Former [2010/29]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:BIOCHEMISCHE MARKER ZUR BEWERTUNG EINES CVD-RISIKOS[2010/29]
English:BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT[2010/29]
French:MARQUEURS BIOCHIMIQUES POUR UNE ÉVALUATION DU RISQUE DE MALADIE CARDIOVASCULAIRE[2010/29]
Entry into regional phase28.04.2010National basic fee paid 
28.04.2010Designation fee(s) paid 
28.04.2010Examination fee paid 
Examination procedure28.04.2010Amendment by applicant (claims and/or description)
28.04.2010Examination requested  [2010/29]
22.09.2010Despatch of a communication from the examining division (Time limit: M06)
22.03.2011Reply to a communication from the examining division
26.03.2013Despatch of a communication from the examining division (Time limit: M06)
27.09.2013Reply to a communication from the examining division
14.04.2015Despatch of a communication from the examining division (Time limit: M04)
13.08.2015Reply to a communication from the examining division
08.12.2016Despatch of a communication from the examining division (Time limit: M04)
06.04.2017Reply to a communication from the examining division
10.04.2018Despatch of a communication from the examining division (Time limit: M04)
27.04.2018Reply to a communication from the examining division
30.09.2019Cancellation of oral proceeding that was planned for 15.10.2019
15.10.2019Date of oral proceedings (cancelled)
07.11.2019Communication of intention to grant the patent
09.12.2019Fee for grant paid
09.12.2019Fee for publishing/printing paid
09.12.2019Receipt of the translation of the claim(s)
Divisional application(s)EP12185050.7  / EP2538221
EP12185053.1  / EP2538222
EP12185056.4  / EP2538218
EP12185057.2  / EP2538223
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.09.2010
Opposition(s)16.10.2020No opposition filed within time limit [2020/52]
Fees paidRenewal fee
01.09.2010Renewal fee patent year 03
01.09.2011Renewal fee patent year 04
03.09.2012Renewal fee patent year 05
02.09.2013Renewal fee patent year 06
01.09.2014Renewal fee patent year 07
10.11.2015Renewal fee patent year 08
01.09.2016Renewal fee patent year 09
14.09.2017Renewal fee patent year 10
23.10.2018Renewal fee patent year 11
13.09.2019Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.11.2008
AT15.01.2020
CY15.01.2020
CZ15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
MT15.01.2020
NL15.01.2020
PL15.01.2020
RO15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
TR15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
[2022/27]
Former [2022/26]AT15.01.2020
CZ15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
NL15.01.2020
PL15.01.2020
RO15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
TR15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2021/31]AT15.01.2020
CZ15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
MC15.01.2020
NL15.01.2020
PL15.01.2020
RO15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2021/11]AT15.01.2020
CZ15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
NL15.01.2020
PL15.01.2020
RO15.01.2020
SE15.01.2020
SI15.01.2020
SK15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/50]CZ15.01.2020
EE15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
NL15.01.2020
RO15.01.2020
SE15.01.2020
SK15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/49]CZ15.01.2020
FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
NL15.01.2020
RO15.01.2020
SE15.01.2020
SK15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/47]FI15.01.2020
HR15.01.2020
LT15.01.2020
LV15.01.2020
NL15.01.2020
SE15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/40]FI15.01.2020
HR15.01.2020
LV15.01.2020
NL15.01.2020
SE15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
IS15.05.2020
PT07.06.2020
Former [2020/39]FI15.01.2020
HR15.01.2020
LV15.01.2020
NL15.01.2020
SE15.01.2020
BG15.04.2020
NO15.04.2020
GR16.04.2020
PT07.06.2020
Former [2020/38]FI15.01.2020
HR15.01.2020
LV15.01.2020
NL15.01.2020
SE15.01.2020
NO15.04.2020
GR16.04.2020
PT07.06.2020
Former [2020/37]FI15.01.2020
HR15.01.2020
LV15.01.2020
NL15.01.2020
SE15.01.2020
NO15.04.2020
PT07.06.2020
Former [2020/36]FI15.01.2020
NL15.01.2020
NO15.04.2020
PT07.06.2020
Former [2020/35]FI15.01.2020
NL15.01.2020
NO15.04.2020
Former [2020/33]NL15.01.2020
Cited inInternational search[X]WO9924835  (BAYER AG [DE], et al) [X] 1-3,11,12,15-30 * Abstract; p. 1, l. 3-6, p. 2, l. 21ff, p. 9, l. 20; examples 1, 3, 6, 7. *;
 [X]WO9961477  (BAYER AG [DE], et al) [X] 1-3,11,12,15-30 * Abstract; p. 1, l. 5-8, p. 6, 7, 8; examples 1, 3, 9. *;
 [X]EP1182213  (WAKO PURE CHEM IND LTD [JP]) [X] 25-29 * The sequence on p. 16, l. 1 comprises sequence 730; the sequence on p. 16, l. 5 is sequence 678 and comprises sequences 725, 726 and 728; sequence 3 comprises sequences 703 and 729; sequence 4 is a fragment of sequence 684 and comprises sequence 731; and sequence 5 comprises sequence 709. *;
 [X]WO02088750  (OXFORD GLYCOSCIENCES UK LTD [GB], et al) [X] 1-4,6,15-30 * Sequence 150 comprises sequences 727, 732 and 734 of the application; claims 9 and 13. *;
 [X]US6703219  (POTEMPA LAWRENCE A [US], et al) [X] 1-4,6,15-30 * Sequence 9 is a fragment of sequence 683 of the application; col. 3, l. 21-22. *;
 [X]WO2005050224  (EPITOME BIOSYSTEMS INC [US], et al) [X] 1-4,6,15-30 * Sequence 11 is a fragment of sequence 676 and comprises sequences 707 and 708; p. 149, second table. *;
 [X]WO2005124341  (ANDERSON NORMAN LEIGH [US]) [X] 25-29 * Sequence 32 comprises sequence 711 of the application. *;
 [A]US2007099242  (HEINECKE JAY W [US], et al) [A] 1-4,6,15-30 * Abstract; table 5. *;
 [X]WO2007050661  (STC UNM [US], et al) [X] 25-29 * Sequence 10 comprises sequence 729. *;
 [X]  - YING S-C ET AL, "Localization of sequence-determined neoepitopes and neutrophil digestion fragments of C-reactive protein utilizing monoclonal antibodies and synthetic peptides", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 29, no. 5, ISSN 0161-5890, (19920501), pages 677 - 687, (19920501), XP023683021 [X] 1-4,6,15-30 * Abstract; Table 2, 3, Fig. 5 *

DOI:   http://dx.doi.org/10.1016/0161-5890(92)90205-C
 [X]  - BISOENDIAL ET AL, "C-reactive protein and atherogenesis: From fatty streak to clinical event", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, (20070721), vol. 195, no. 2, ISSN 0021-9150, pages e10 - e18, XP022344944 [X] 1-4,6,15-30 * Abstract; p.e13, RH col. par. 2; p. e14, paragraph bridging both columns; p. e14, first paragraph of "7. In summary"; Fig. 1. *

DOI:   http://dx.doi.org/10.1016/j.atherosclerosis.2007.04.053
 [X]  - MOLLOY K J ET AL, "Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity", CIRCULATION, (20040720), vol. 110, no. 3, ISSN 0009-7322, pages 337 - 343, XP002530330 [X] 1-3,11,12,15-30 * Abstract; Discussion. *

DOI:   http://dx.doi.org/10.1161/01.CIR.0000135588.65188.14
 [X]  - SATTA ET AL, "Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples", JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, (19950801), vol. 22, no. 2, ISSN 0741-5214, pages 155 - 160, XP005141626 [X] 1-3,11,12,15-30 * abstract *

DOI:   http://dx.doi.org/10.1016/S0741-5214(95)70110-9
 [X]  - ZANNAD F ET AL, "Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.", CIRCULATION 28 NOV 2000, (20001128), vol. 102, no. 22, ISSN 1524-4539, pages 2700 - 2706, XP002530331 [X] 1-3,11,12,15-30 * Abstract; p. 2701 Laboratory Analysis. *
 [X]  - LIN Y H ET AL, "The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 39, no. 9, ISSN 0009-9120, (20060901), pages 861 - 866, (20060901), XP025059081 [X] 1-3,11,12,15-30 * Abstract; p. 862 Blood sampling and determination of PINP and PIIINP. *

DOI:   http://dx.doi.org/10.1016/j.clinbiochem.2006.05.017
ExaminationWO9508115
 EP0829724
 WO9924835
 WO9961477
 US6010862
 US2003049715
 US2004048321
    - U BECKER ET AL, "Production and specificity of antibodies against the aminoterminal region in type III collagen.", IMMUNOLOGY, (19760101), vol. 31, pages 57 - 65, XP055055119
    - SUNDSTROM JOHAN ET AL, "Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events", CURRENT OPINION IN LIPIDOLOGY, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, (20060201), vol. 17, no. 1, ISSN 0957-9672, pages 45 - 53, XP009112009
    - HISAE H ET AL, "Repeated helical epitopes of defined amino acid sequence in human type III collagen identified by monoclonal antibodies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 29, no. 6, doi:10.1016/0161-5890(92)90186-2, ISSN 0161-5890, (19920601), pages 759 - 770, (19920601), XP023682474

DOI:   http://dx.doi.org/10.1016/0161-5890(92)90186-2
    - MOLLOY K J ET AL, "Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity", CIRCULATION, AMERICAN HEART ASSOCIATION, US, (20040720), vol. 110, no. 3, doi:10.1161/01.CIR.0000135588.65188.14, ISSN 0009-7322, pages 337 - 343, XP002530330

DOI:   http://dx.doi.org/10.1161/01.CIR.0000135588.65188.14
    - SATTA ET AL, "Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples", JOURNAL OF VASCULAR SURG, C.V. MOSBY CO., ST. LOUIS, MO, US, (19950801), vol. 22, no. 2, doi:10.1016/S0741-5214(95)70110-9, ISSN 0741-5214, pages 155 - 160, XP005141626

DOI:   http://dx.doi.org/10.1016/S0741-5214(95)70110-9
    - ZANNAD F ET AL, "Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators", CIRCULATION, AMERICAN HEART ASSOCIATION, INC, US, (20001128), vol. 102, no. 22, ISSN 1524-4539, pages 2700 - 2706, XP002530331
    - LIN Y H ET AL, "The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 39, no. 9, doi:10.1016/J.CLINBIOCHEM.2006.05.017, ISSN 0009-9120, (20060901), pages 861 - 866, (20060901), XP025059081

DOI:   http://dx.doi.org/10.1016/j.clinbiochem.2006.05.017
    - NATASHA BARASCUK ET AL, "Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen-A novel biomarker of atherosclerotic plaque remodeling", CLINICAL BIOCHEMISTRY, ELSEVIER INC, US, CA, vol. 44, no. 10-11, doi:10.1016/J.CLINBIOCHEM.2011.04.004, ISSN 0009-9120, (20110701), pages 900 - 906, (20110430), XP002679243

DOI:   http://dx.doi.org/10.1016/j.clinbiochem.2011.04.004
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.